calendar
3,752 catalysts · 3,728 phase readout · 2,104 8k filing · 276 earnings · 172 phase 2 completion · 138 grant · 133 drug shortage
3,752 catalysts · 3,728 phase readout · 2,104 8k filing · 276 earnings · 172 phase 2 completion · 138 grant · 133 drug shortage
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track No User Fee. Product code: MWG. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: QZH. Advisory committee: TX. Decision: APPR
Supplement type: Real-Time Process. Product code: NIK. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track No User Fee. Product code: NAW. Advisory committee: RA. Decision: APPR
Supplement type: 30-Day Notice. Product code: MRA. Advisory committee: OR. Decision: OK30
Supplement type: 30-Day Notice. Product code: QPY. Advisory committee: PM. Decision: OK30
Supplement type: Real-Time Process. Product code: LWP. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: NVN. Advisory committee: CV. Decision: APPR
Supplement type: Normal 180 Day Track. Product code: DSQ. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: LWS. Advisory committee: CV. Decision: APPR
Supplement type: Special (Immediate Track). Product code: NPW. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: NVN. Advisory committee: CV. Decision: APPR
Supplement type: Real-Time Process. Product code: QFV. Advisory committee: CV. Decision: APPR
Supplement type: Special (Immediate Track). Product code: QQK. Advisory committee: GU. Decision: APPR
Supplement type: 30-Day Notice. Product code: NJL. Advisory committee: OR. Decision: OK30
Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration
Sponsor: University of Alberta. Phase: . Conditions: Low Back Pain
Therapy area: Ophthalmology. Indication: Choroidal Neovascularization
Therapy area: Genetic Disorders. Indication: Duchenne Muscular Dystrophy
Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion
Therapy area: Ophthalmology. Indication: Diabetic Retinopathy
Therapy area: Ophthalmology. Indication: Diabetic Macular Edema
Sponsor: Beijing Sport University. Phase: NA. Conditions: Patellofemoral Pain
Sponsor: Definium Therapeutics US, Inc.. Phase: PHASE3. Conditions: Major Depressive Disorder
Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Unresectable Melanoma
Sponsor: The University of Queensland. Phase: NA. Conditions: Blood Culture Contamination, Infection
Sponsor: Mayo Clinic. Phase: . Conditions: Spontaneous Coronary Artery Dissection
Sponsor: Riphah International University. Phase: NA. Conditions: Adhesive Capsulitis of the Shoulder
Sponsor: October 6 University. Phase: NA. Conditions: Cerebral Palsy
Sponsor: Liverpool School of Tropical Medicine. Phase: NA. Conditions: Crimean-Congo Haemorrhagic Fever
Sponsor: Eilean Therapeutics AU Pty Ltd. Phase: PHASE1. Conditions: Healthy Volunteers
Sponsor: Chandan Sen. Phase: NA. Conditions: Wound Heal, Wound Infection, Wound Healing Delayed, Wound of Skin, Infections
Sponsor: National Institute of Mental Health (NIMH). Phase: . Conditions: Neuropsychiatric Disorder, Neurological Disorder, Neurodevelopmental Disorder, Sleep
Sponsor: University of Washington. Phase: NA. Conditions: Mental Health Disorder
Sponsor: Nanchang University. Phase: NA. Conditions: Natural Orifice Specimen Extraction Surgery, Robotic Surgery, Short-term Outcomes
Sponsor: Mayo Clinic. Phase: PHASE4. Conditions: Endometrial Carcinoma
Sponsor: Alumis Inc. Phase: PHASE1. Conditions: Healthy Volunteer
Sponsor: Hu Liangshuo. Phase: . Conditions: Liver Transplantation, Hepatocellular Carcinoma (HCC), Tyrosine Kinase Inhibitor, Survival Rate
Sponsor: Institute of Hematology & Blood Diseases Hospital, China. Phase: PHASE2. Conditions: Immune Thrombocytopenia, Treatment
Sponsor: ECOG-ACRIN Cancer Research Group. Phase: PHASE2. Conditions: Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Systemic Lupus Erythematosus (SLE)
Sponsor: Asian Institute of Gastroenterology, India. Phase: NA. Conditions: Walled Off Necrosis
Sponsor: Echosens. Phase: NA. Conditions: Non-Alcoholic Fatty Liver Disease, Liver Disease; Alcohol-Related
Sponsor: Université de Reims Champagne-Ardenne. Phase: . Conditions: Human Immunodeficiency Virus (HIV)
Sponsor: Smith & Nephew, Inc.. Phase: . Conditions: Arthroplasty, Replacement, Knee
Sponsor: Iantrek, Inc.. Phase: . Conditions: Open-angle Glaucoma (OAG)
Sponsor: Balnear and Rehabilitation Sanatorium Techirghiol. Phase: NA. Conditions: Shoulder Tendinopathy